SYRS insider transaction filings

Syros Pharmaceuticals, Inc. — 29 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2024-12-04. Screen SYRS transaction legs live →

Insider transaction summary — last 90 days

No Form 4 filings for SYRS between 2026-06-11 and 2026-09-09. The table below lists the most recent filings on record.

Recent Form 4 filings — Syros Pharmaceuticals, Inc.

FiledFormInsiderReported transactionsSource
2024-12-044Simonian Nancy A — DirectorSale (S): 37,070 @ $0.27EDGAR
2024-11-274Simonian Nancy A — DirectorSale (S): 134,713 @ $0.27EDGAR
2024-11-204Stephens Kristin — Chief Development OfficerSale (S): 36,133 @ $0.22EDGAR
2024-11-204Roth David — Chief Medical OfficerSale (S): 12,099 @ $0.20EDGAR
2024-11-204Chee Conley — President & CEO, DirectorSale (S): 134,797 @ $0.20EDGAR
2024-11-204Haas Jason — Chief Financial OfficerSale (S): 137,803 @ $0.21EDGAR
2024-11-204Quirk Gerald E — Chief Legal & Compliance OfficSale (S): 46,657 @ $0.22EDGAR
2024-11-044Roth David — Chief Medical OfficerOption exercise (M): 18,875 · Tax withholding (F): 6,776 @ $2.09 · Option exercise (M): 18,875 (derivative) @ $0EDGAR
2024-11-044Haas Jason — Chief Financial OfficerOption exercise (M): 18,875 · Tax withholding (F): 5,624 @ $2.09 · Option exercise (M): 18,875 (derivative) @ $0EDGAR
2024-11-044Chee Conley — President & CEO, DirectorOption exercise (M): 17,000 · Tax withholding (F): 8,707 @ $2.09 · Option exercise (M): 17,000 (derivative) @ $0EDGAR
2024-11-044Stephens Kristin — Chief Development OfficerOption exercise (M): 17,000 · Tax withholding (F): 6,104 @ $2.09 · Option exercise (M): 17,000 (derivative) @ $0EDGAR
2024-11-044Simonian Nancy A — DirectorOption exercise (M): 40,125 · Option exercise (M): 40,125 (derivative) @ $0EDGAR
2024-10-024Quirk Gerald E — Chief Legal & Compliance OfficOption exercise (M): 10,000 · Tax withholding (F): 3,100 @ $2.10 · Option exercise (M): 10,000 (derivative) @ $0EDGAR
2024-09-184Young Richard A — DirectorOption exercise (M): 2,667 · Option exercise (M): 2,667 (derivative) @ $0EDGAR
2024-09-184AKKARAJU SRINIVAS — DirectorOption exercise (M): 2,667 · Option exercise (M): 2,667 (derivative) @ $0EDGAR
2024-09-124Haas Jason — Chief Financial OfficerPurchase (P): 35,363 @ $1.55 · Purchase (P): 19,293 @ $1.58 · Purchase (P): 45,344 @ $1.68EDGAR
2024-09-124Chee Conley — President & CEO, DirectorPurchase (P): 50,000 @ $1.51 · Purchase (P): 50,000 @ $1.71EDGAR
2024-07-024Young Richard A — DirectorSale (S): 34,837 @ $5.12EDGAR
2024-06-074Eckhardt Sue Gail — DirectorGrant/award (A): 4,000 @ $0 · Grant/award (A): 6,000 (derivative) @ $0EDGAR
2024-06-074OH ANDREW M. — DirectorGrant/award (A): 4,000 @ $0 · Grant/award (A): 6,000 (derivative) @ $0EDGAR
2024-06-074Young Richard A — DirectorGrant/award (A): 4,000 @ $0 · Grant/award (A): 6,000 (derivative) @ $0EDGAR
2024-06-074Simonian Nancy A — DirectorGrant/award (A): 4,000 @ $0 · Grant/award (A): 6,000 (derivative) @ $0EDGAR
2024-06-074Dunsire Deborah — DirectorGrant/award (A): 6,000 (derivative) @ $0 · Grant/award (A): 4,000 (derivative) @ $0EDGAR
2024-06-074Fanucci Marsha — DirectorGrant/award (A): 4,000 @ $0 · Grant/award (A): 6,000 (derivative) @ $0EDGAR
2024-06-074AKKARAJU SRINIVAS — DirectorGrant/award (A): 6,000 (derivative) @ $0 · Grant/award (A): 4,000 (derivative) @ $0EDGAR
2024-06-074TYSON TIMOTHY — DirectorGrant/award (A): 4,000 @ $0 · Grant/award (A): 6,000 (derivative) @ $0EDGAR
2024-06-074WIRTH PETER — DirectorGrant/award (A): 4,000 @ $0 · Grant/award (A): 6,000 (derivative) @ $0EDGAR
2024-06-044Dunsire Deborah — DirectorOption exercise (M): 4,000 · Option exercise (M): 4,000 (derivative) @ $0EDGAR
2024-06-044AKKARAJU SRINIVAS — DirectorOption exercise (M): 4,000 · Option exercise (M): 4,000 (derivative) @ $0EDGAR

Recent 8-K events — Syros Pharmaceuticals, Inc.

FiledFormItems reportedSource
2025-03-048-K8.01 — Other EventsEDGAR
2025-02-288-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2025-01-088-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2024-12-068-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2024-11-188-K1.02 — Termination of a Material Definitive Agreement
2.04 — Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
?
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
EDGAR
2024-11-138-K2.04 — Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2024-09-058-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2024-08-128-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2024-06-068-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.07 — Submission of Matters to a Vote of Security Holders
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=SYRS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →